Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry.
Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation.
The FDA has approved Rapiblyk (landiolol), an ultra-short-acting beta-blocker, for the short-term treatment of supraventricular tachycardia (SVT), including atrial...
The European Commission approved BeiGene’s tislelizumab (TEVIMBRA), combined with chemotherapy, for first-line treatment of esophageal squamous cell carcinoma (ESCC)...